{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:21:13Z","timestamp":1769520073526,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaad.2023.03.048","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T20:56:33Z","timestamp":1680987393000},"page":"1263-1264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cutaneous adverse reactions to Bruton tyrosine kinase inhibitors: Banal to brutal"],"prefix":"10.1016","volume":"88","author":[{"given":"Warren R.","family":"Heymann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.03.048_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.708071","article-title":"Bruton tyrosine kinase inhibition and its role as an emerging treatment in pemphigus","volume":"8","author":"Patsatsi","year":"2021","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.jaad.2023.03.048_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.03.048_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103696","article-title":"Ibrutinib-associated dermatologic toxicities: a systematic review and meta-analysis","volume":"174","author":"Nocco","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2023.03.048_bib4","doi-asserted-by":"crossref","unstructured":"Singer S, Tan SY, Dewan AK, et\u00a0al. Cutaneous eruptions from ibrutinib resembling EGFR inhibitor-induced dermatologic adverse events. Preprint. Posted online December 20, 2019. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.031","DOI":"10.1016\/j.jaad.2019.12.031"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.048_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11899-020-00576-3","article-title":"Management of ibrutinib toxicities: a practical guide","volume":"15","author":"Lasica","year":"2020","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223005406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223005406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:23:55Z","timestamp":1759274635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223005406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0190962223005406"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.048","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse reactions to Bruton tyrosine kinase inhibitors: Banal to brutal","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}